Prescribing information



LUCENTIS offers patients efficacy across multiple indications1


The anti-VEGF with the broadest range of retinal indications1

Click the button below to see the key efficacy data for LUCENTIS in the treatment of neovascular (wet) age-related macular degeneration (AMD). 



Resources to help you with your LUCENTIS patients


Preview of an Educational booklet, image of an eye- resources for HCPs.

Resources for HCPs

Access the resources for HCPs >

Document with image of a lady smiling, with text 'understanding diabetic macular oedema (DMO) & what to expect from your lucentis treatment' on it. Resources for HCPs to share with patients.

Resources for HCPs to share with patients

Access the patient resources >


We cover a variety of topics about a-VEGF patients, treatment and service impact due to COVID-19 in a variety of webinars and podcasts. 


Image icon of a screen with people icons and a speech bubble representing webinar highlights.

Webinar highlights 

Access the webinar highlights >

Image icon of a microphone with sound waves coming out representing opthalmology podcasts.

Ophthalmology podcasts

Access the ophthalmology podcasts >



*LUCENTIS 0.2 mg is indicated in preterm infants for:1
The treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.

DMO, diabetic macular oedema; CNV, choroidal neovascularisation; HCP, healthcare professional; PDR, proliferative diabetic retinopathy; ROP, retinopathy of prematurity; RVO, retinal vein occlusion; RWE, real-world evidence; T&E, treat & extend; VEGF, vascular endothelial growth factor; wAMD, wet age-related macular degeneration;



  1. Lucentis (ranibizumab) Summary of Product Characteristics, July 2020.
  2. Novartis Data on File. Novartis Pharma AG, LUCDOF21-002, October 2019.
  3. Novartis Data on File. Novartis Pharma AG, LUCDOF21-003, October 2019.
  4. Dorairaj E, et al. Ranibizumab in diabetic macular oedema: 2 year audit data. Presented at ESCRS 2017, Maastricht, The Netherlands.     
  5. Prakash, P, et al. To determine the efficacy of treatment of Ranibizumab over a period of 5 years in patients with DMO at PAH, Harlow, presented at Royal College of Ophthalmology congress 2021.    
  6. Mitchell P, et al. Effectiveness and safety of ranibizumab 0.5 mg in treatment-naïve patients with diabetic macular edema: Results from the real-world global LUMINOUS study. PLoS One. 2020;15(6):32492069.
Rate this content: 
Average: 2.6 (69 votes)
UK | December 2021 | 176510

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at